These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 18089329

  • 1. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 2. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 3. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience.
    Kandus A, Grego K, Arnol M, Kovac D, Lindic J, Buturović J, Ponikvar R, Bren AF.
    Transplant Proc; 2006 Nov 27; 38(9):2853-5. PubMed ID: 17112847
    [Abstract] [Full Text] [Related]

  • 4. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 27; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 5. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May 27; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 6. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S, Colak T, Baskin E, Sevmis S, Ozdemir H, Moray G, Karakayali H, Haberal M.
    Transplant Proc; 2011 Mar 27; 43(2):453-7. PubMed ID: 21440732
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
    González E, Gutiérrez E, Hernández Y, Roselló G, Gutiérrez MJ, Martínez EG, Manzanera MJ, García JA, Praga M, Morales JM, Andrés A.
    Transplant Proc; 2005 Nov 27; 37(9):3736-7. PubMed ID: 16386522
    [Abstract] [Full Text] [Related]

  • 8. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Nov 27; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 9. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT.
    Transplant Proc; 2006 Sep 27; 38(7):2025-8. PubMed ID: 16979988
    [Abstract] [Full Text] [Related]

  • 10. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D, Kotnik V, Kandus A.
    Transplant Proc; 2005 Dec 27; 37(10):4230-4. PubMed ID: 16387086
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB.
    Transplantation; 2008 Nov 15; 86(9):1241-8. PubMed ID: 19005406
    [Abstract] [Full Text] [Related]

  • 12. [Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center)].
    Rainiene T, Dobrovolskiene R, Dainys B, Kucinskis G, Zelvys A.
    Medicina (Kaunas); 2007 Nov 15; 43 Suppl 1():109-13. PubMed ID: 17551287
    [Abstract] [Full Text] [Related]

  • 13. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 15; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 14. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 15. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S, Guerra J, Silva S, Santana A, Mil-Homens C, Prata MM.
    Transplant Proc; 2008 Apr 20; 40(3):693-6. PubMed ID: 18454989
    [Abstract] [Full Text] [Related]

  • 16. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.
    Transplant Proc; 2001 Aug 20; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract] [Full Text] [Related]

  • 17. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
    Naderi GH, Mehraban D, Ganji MR, Jafarpouriani M, Latif AH.
    Transplant Proc; 2009 Sep 20; 41(7):2768-71. PubMed ID: 19765430
    [Abstract] [Full Text] [Related]

  • 18. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD, Rajagopalan PR, Hall M.
    Transplantation; 1999 Jan 27; 67(2):276-84. PubMed ID: 10075594
    [Abstract] [Full Text] [Related]

  • 19. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S, Sumethkul V, Mavichak V, Lertsithichai P, Jirasiritham S.
    Transplant Proc; 2004 Sep 27; 36(7):2110-2. PubMed ID: 15518764
    [Abstract] [Full Text] [Related]

  • 20. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K, Kraft K, Thielke J, Oberholzer J, Sankary H, Testa G, Benedetti E.
    Transplant Proc; 2005 Mar 27; 37(2):899-902. PubMed ID: 15848569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.